相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 英文名:
Daudi
- 库存:
100
- 供应商:
中乔新舟
- 品系:
原代细胞
- 运输方式:
常温
- 年限:
液氮长期
- 生长状态:
悬浮生长
- 规格:
T25
|
产品名称 |
MEG-01人成巨核细胞白血病细胞 |
|
货号 |
ZQ0431 |
|
产品介绍 |
MEG-01细胞源自一位CML患者成巨核细胞转换期的骨髓细胞。细胞质因子Ⅷ和表面球蛋白Ⅱb/Ⅲa、α醋酸萘酯酶和酸性磷酸酶阳性;髓过氧化物酶、α-丁酸萘酯酶、氯化醋酸AS-D萘苯酚酯酶和碱性磷酸酶阴性。用单克隆抗体BA-1(抗B细胞、粒性白细胞),HPL-3(抗球蛋白Ⅱb/Ⅲa)和20.3(抗单核细胞、血小板)染色成阳性,其他淋巴和骨髓类抗体成阴性。 |
|
种属 |
人 |
|
性别/年龄 |
男性/55岁 |
|
组织 |
骨; 骨髓 |
|
疾病 |
急变期慢性粒细胞白血病 |
|
生物安全等级 |
BSL-1 |
|
STR位点信息 |
Amelogenin X,Y CSF1PO 10 D2S1338 19 D3S1358 15 D5S818 13 D7S820 11 D8S1179 14,15 D13S317 8 D16S539 9 D18S51 18,22 D19S433 14,16 D21S11 29 FGA 26 Penta D 11,13 Penta E 15 TH01 7 TPOX 8,11 vWA 16 |
|
细胞类型 |
巨核细胞 |
|
形态学 |
淋巴母细胞 |
|
生长方式 |
混合:粘附和悬浮 |
|
倍增时间 |
36-48 hours (PubMed=2998511); ~35 hours (DSMZ=ACC-364) |
|
培养基和添加剂 |
RPMI-1640(中乔新舟 货号:ZQ-200)+20%胎牛血清(中乔新舟 货号:ZQ0500)+1%双抗(品牌:中乔新舟 货号:CSP006) |
|
推荐完全培养基货号 |
ZM0431 |
|
培养条件 |
95%空气,5%二氧化碳;37℃ |
|
基因表达 |
Amelogenin: X,Y CSF1PO: 10 D13S317: 8 D16S539: 9 D5S818: 13 D7S820: 11 THO1: 7 TPOX: 8,11 vWA: 16 |
|
保藏机构 |
ATCC; CRL-2021BCRC; 60238BCRJ; 0262DSMZ; ACC-364 |
|
供应限制 |
仅供科研使用 |
上海中乔新舟生物科技有限公司成立于2011年,历经十多年发展,主要专注于细胞生物学产品的研究和开发,专注于为药企、各类科研机构及CRO企业提供符合标准规范的细胞培养服务、细胞培养基、细胞检测试剂盒、细胞培养试剂,胎牛血清和细胞生物学技术服务等。
公司一直致力于为高等院校、研究机构、医院、CRO及CDMO企业提供细胞培养完整解决方案,这些产品旨在满足细胞培养的多样需求,确保实验和研究的有效进行。引用中乔新舟(ZQXZBIO)产品和服务的文献超数千篇。

产品服务
细胞资源:原代细胞、细胞株、干细胞、示踪细胞、耐药株细胞、永生化细胞等基因工程细胞。
试剂产品:胎牛血清、完全培养基(适用于原代细胞及细胞株)、无血清培养基、基础培养基、细胞转染试剂、重组因子、胰酶和双抗等等细胞培养所有实验相关产品。
技术服务:稳转株构建、原代细胞分离、特殊培养基定制服务、细胞检测等。

目前产品已经畅销国内30多个省市,与客户建立长期的合作伙伴关系,共同实现成功。全体员工将不懈努力,继续为科研人员提供优良的产品和服务,致力成为全球细胞培养领域的参与者。

企业愿景
致力于成为国内细胞培养基产业的佼佼者,生物医药领域上游原材料的优良提供商。
企业使命
成长为专业细胞系及原代细胞培养供应商、专业细胞培养基及培养试剂生产商。
企业荣誉


风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验论文标题: Knockdown of long non‑coding RNA ANRIL inhibits the proliferation and promotes the apoptosis of Burkitt lymphoma cells through the TGF‑β1 signaling pathway
DOI: 10.3892/mmr.2020.11785
发表时间: 2020-12-15
期刊: Molecular Medicine Reports
影响因子: 2.1
货号: ZQ0432
产品名称: Daudi cells
PubMed=4174339
Klein E., Klein G., Nadkarni J.S., Nadkarni J.J., Wigzell H., Clifford P.
Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines.
Cancer Res. 28:1300-1310(1968)
PubMed=4878906; DOI=10.1084/jem.128.5.1011
Klein G., Pearson G.R., Nadkarni J.S., Nadkarni J.J., Klein E., Henle G., Henle W., Clifford P.
Relation between Epstein-Barr viral and cell membrane immunofluorescence of Burkitt tumor cells. I. Dependence of cell membrane immunofluorescence on presence of EB virus.
J. Exp. Med. 128:1011-1020(1968)
PubMed=4178827; DOI=10.1002/1097-0142(196901)23:1<64::AID-CNCR2820230107>3.0.CO;2-M
Nadkarni J.S., Nadkarni J.J., Clifford P., Manolov G., Fenyo E.-M., Klein E.
Characteristics of new cell lines derived from Burkitt lymphomas.
Cancer 23:64-79(1969)
PubMed=4321974
Maurer B.A., Imamura T., Wilbert S.M.
Incidence of EB virus-containing cells in primary and secondary clones of several Burkitt lymphoma cell lines.
Cancer Res. 30:2870-2875(1970)
PubMed=4122458; DOI=10.1002/ijc.2910100108
Klein G., Dombos L., Gothoskar B.
Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus.
Int. J. Cancer 10:44-57(1972)
PubMed=5021706
van Furth R., Gorter H., Nadkarni J.S., Nadkarni J.J., Klein E., Clifford P.
Synthesis of immunoglobulins by biopsied tissues and cell lines from Burkitt's lymphoma.
Immunology 22:847-857(1972)
PubMed=4364259; DOI=10.1002/ijc.2910110210
Klein G., Dombos L.
Relationship between the sensitivity of EBV-carrying lymphoblastoid lines to superinfection and the inducibility of the resident viral genome.
Int. J. Cancer 11:327-337(1973)
PubMed=170370; DOI=10.1099/0022-1317-28-2-207
Adams A., Strander H., Cantell K.
Sensitivity of the Epstein-Barr virus transformed human lymphoid cell lines to interferon.
J. Gen. Virol. 28:207-217(1975)
PubMed=216485
Higgins N.P., Strauss B.S.
Differences in the ability of human lymphoblastoid lines to exclude bromodeoxyuridine and in their sensitivity to methyl methanesulfonate and to incorporated [3H]thymidine.
Cancer Res. 39:312-320(1979)
PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x
Povey S., Jeremiah S., Arthur E., Steel M., Klein G.
Differences in genetic stability between human cell lines from patients with and without lymphoreticular malignancy.
Ann. Hum. Genet. 44:119-133(1980)
PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)
PubMed=6286763; DOI=10.4049/jimmunol.129.3.1336
Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd H.D., Parsons R.G.
Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type.
J. Immunol. 129:1336-1342(1982)
PubMed=6806672; DOI=10.1038/298474a0
Lenoir G.M., Preud'homme J.-L., Bernheim A., Berger R.
Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma.
Nature 298:474-476(1982)
PubMed=6954533; DOI=10.1073/pnas.79.7.2194
Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A., Aaronson S.A., Wong-Staal F.
Differential expression of the amv gene in human hematopoietic cells.
Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982)
PubMed=6186604; DOI=10.1007/BF00364753
de Preval C., Mach B.
The absence of beta 2-microglobulin in Daudi cells: active gene but inactive messenger RNA.
Immunogenetics 17:133-140(1983)
PubMed=11894933; DOI=10.1002/j.1460-2075.1983.tb01412.x
Rosa F.M., Berissi H., Weissenbach J., Maroteaux L., Fellous M., Revel M.
The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon.
EMBO J. 2:239-243(1983)
PubMed=6200433; DOI=10.1007/BF00364762
Brodsky F.M.
A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes.
Immunogenetics 19:179-194(1984)
PubMed=6231253; DOI=10.1002/ijc.2910330407
Ehlin-Henriksson B., Klein G.
Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation.
Int. J. Cancer 33:459-463(1984)
PubMed=6500159; DOI=10.1159/000163283
Gershwin M.E., Lentz D., Owens R.B.
Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice.
Exp. Cell Biol. 52:361-370(1984)
PubMed=6547209; DOI=10.1038/309592a0
Rabbitts T.H., Forster A., Hamlyn P.H., Baer R.
Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma.
Nature 309:592-597(1984)
PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)
PubMed=6592381; DOI=10.1093/jnci/73.4.841
Favrot M.-C., Philip I., Philip T., Portoukalian J., Dore J.-F., Lenoir G.M.
Distinct reactivity of Burkitt's lymphoma cell lines with eight monoclonal antibodies correlated with the ethnic origin.
J. Natl. Cancer Inst. 73:841-847(1984)
PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- 1 carboxylic esterase.
Leuk. Res. 9:209-229(1985)
PubMed=2998993
Steel C.M., Morten J.E.N., Foster E.
The cytogenetics of human B lymphoid malignancy: studies in Burkitt's lymphoma and Epstein-Barr virus-transformed lymphoblastoid cell lines.
IARC Sci. Publ. 60:265-292(1985)
PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- III Beta-hexosaminidase (E.C. 3.2.1.30).
Leuk. Res. 9:549-559(1985)
PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.
Leuk. Res. 9:537-548(1985)
PubMed=3905596
Favrot M.-C., Philip I., Philip T., Cabrillat H., Pinatel C., Dore J.-F., Lenoir G.M.
Immunophenotypic classification of 28 Burkitt cell lines with monoclonal antibodies and reagent selection for bone-marrow purging.
IARC Sci. Publ. 60:447-452(1985)
PubMed=3080238
Sieverts H., Alabaster O., Goldschmidts W., Magrath I.T.
Expression of surface antigens during the cell cycle in different growth phases of American and African Burkitt's lymphoma cell lines.
Cancer Res. 46:1182-1188(1986)
PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)
PubMed=3785169; DOI=10.1128/mcb.6.5.1374-1378.1986
Dron M., Modjtahedi N., Brison O., Tovey M.G.
Interferon modulation of c-myc expression in cloned Daudi cells: relationship to the phenotype of interferon resistance.
Mol. Cell. Biol. 6:1374-1378(1986)
PubMed=3026973; DOI=10.1002/ijc.2910390215
Ehlin-Henriksson B., Manneborg-Sandlund A., Klein G.
Expression of B-cell-specific markers in different Burkitt lymphoma subgroups.
Int. J. Cancer 39:211-218(1987)
PubMed=3034807; DOI=10.1002/ijc.2910390622
Ohno H., Fukuhara S., Takahashi R., Mihara K.-i., Sugiyama T., Doi S., Uchino H., Toyoshima K.
c-yes and bcl-2 genes located on 18q21.3 in a follicular lymphoma cell line carrying a t(14;18) chromosomal translocation.
Int. J. Cancer 39:785-788(1987)
PubMed=3116544; DOI=10.1073/pnas.84.19.6835
Haluska F.G., Tsujimoto Y., Croce C.M.
The t(8;14) chromosome translocation of the Burkitt lymphoma cell line Daudi occurred during immunoglobulin gene rearrangement and involved the heavy chain diversity region.
Proc. Natl. Acad. Sci. U.S.A. 84:6835-6839(1987)
PubMed=2470097; DOI=10.1073/pnas.86.9.3257
Shtivelman E., Henglein B., Groitl P., Lipp M., Bishop J.M.
Identification of a human transcription unit affected by the variant chromosomal translocations 2;8 and 8;22 of Burkitt lymphoma.
Proc. Natl. Acad. Sci. U.S.A. 86:3257-3260(1989)
PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x
Nakano A., Harada T., Morikawa S., Kato Y.
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Acta Pathol. Jpn. 40:107-115(1990)
PubMed=2052620; DOI=10.1073/pnas.88.12.5413
Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.
Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991)
CLPUB00447
Mulivor R.A., Suchy S.F.
1992/1993 catalog of cell lines. NIGMS human genetic mutant cell repository. 16th edition. October 1992.
(In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992)
PubMed=8301159; DOI=10.1089/jir.1993.13.377
Dron M., Tovey M.G.
Interferon-resistant Daudi cells are deficient in interferon-alpha-induced ISGF3 alpha activation, but remain sensitive to the interferon-alpha-induced increase in ISGF3 gamma content.
J. Interferon Res. 13:377-383(1993)
PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418
Jain V.K., Judde J.-G., Max E.E., Magrath I.T.
Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
J. Immunol. 150:5418-5428(1993)
PubMed=8197130; DOI=10.1073/pnas.91.11.4751
Bicknell D.C., Rowan A.J., Bodmer W.F.
Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors.
Proc. Natl. Acad. Sci. U.S.A. 91:4751-4755(1994)
PubMed=7849311; DOI=10.1182/blood.V85.4.893.bloodjournal854893
Stranks G., Height S.E., Mitchell P., Jadayel D.M., Yuille M.A.R., De Lord C., Clutterbuck R.D., Treleaven J.G., Powles R.L., Nacheva E., Oscier D.G., Karpas A., Lenoir G.M., Smith S.D., Millar J.L., Catovsky D., Dyer M.J.S.
Deletions and rearrangement of CDKN2 in lymphoid malignancy.
Blood 85:893-901(1995)
PubMed=8558913
Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M., Imaizumi M., Endo M., Takano N., Konno T.
Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture.
Leukemia 10:102-105(1996)
PubMed=8558920
Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M., Quentmeier H., Drexler H.G.
The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.
Leukemia 10:142-149(1996)
PubMed=8847894
Tani A., Tatsumi E., Nakamura F., Kumagai S., Kosaka Y., Sano K., Nakamura H., Amakawa R., Ohno H.
Sensitivity to dexamethasone and absence of bcl-2 protein in Burkitt's lymphoma cell line (Black93) derived from a patient with acute tumor lysis syndrome: comparative study with other BL and non-BL lines.
Leukemia 10:1592-1603(1996)
PubMed=9192833
Cherney B.W., Bhatia K.G., Sgadari C., Gutierrez M.I., Mostowski H.S., Pike S.E., Gupta G., Magrath I.T., Tosato G.
Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells.
Cancer Res. 57:2508-2515(1997)
PubMed=9473234; DOI=10.1182/blood.V91.5.1680
Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.
p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma.
Blood 91:1680-1687(1998)
PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x
Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.
Frameshift mutations of the hMSH6 gene in human leukemia cell lines.
Jpn. J. Cancer Res. 89:33-39(1998)
PubMed=9685479; DOI=10.1093/nar/26.16.3651
Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T., Roos G.
Telomere analysis by fluorescence in situ hybridization and flow cytometry.
Nucleic Acids Res. 26:3651-3656(1998)
PubMed=9737686; DOI=10.1038/sj.leu.2401112
Zhang W., Ohnishi K., Shigeno K., Fujisawa S., Naito K., Nakamura S., Takeshita K., Takeshita A., Ohno R.
The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.
Leukemia 12:1383-1391(1998)
PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x
Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T., Aizawa Y., Ueda R., Seto M.
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Jpn. J. Cancer Res. 89:712-718(1998)
PubMed=9973220
Gutierrez M.I., Cherney B.W., Hussain A., Mostowski H.S., Tosato G., Magrath I.T., Bhatia K.G.
Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis.
Cancer Res. 59:696-703(1999)
PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.
Leuk. Res. 24:255-262(2000)
PubMed=11021758; DOI=10.1038/sj.leu.2401891
Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A., Gaulton G.N., Ratajczak M.Z.
Biological significance of the expression of HIV-related chemokine coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic cell lines.
Leukemia 14:1821-1832(2000)
PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000),255-262.
Leuk. Res. 25:275-278(2001)
PubMed=12145705; DOI=10.1038/sj.leu.2402519
Langerak A.W., Moreau E., van Gastel-Mol E.J., van der Burg M., van Dongen J.J.M.
Detection of clonal EBV episomes in lymphoproliferations as a diagnostic tool.
Leukemia 16:1572-1573(2002)
PubMed=12967475; DOI=10.1111/j.1349-7006.2003.tb01518.x
Maesako Y., Uchiyama T., Ohno H.
Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma.
Cancer Sci. 94:774-781(2003)
PubMed=14504097; DOI=10.1182/blood-2003-02-0418
Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R., Tsuchida M., Sugita K., Ida K., Hayashi Y.
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Blood 103:1085-1088(2004)
PubMed=15028022; DOI=10.1111/j.1440-1827.2004.01612.x
Kamimura K., Hojo H., Abe M.
Characterization of expression of protein kinase C isozymes in human B-cell lymphoma: relationship between its expression and prognosis.
Pathol. Int. 54:224-230(2004)
PubMed=19358282; DOI=10.1002/ijc.24351
Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M., Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.
Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
Int. J. Cancer 125:212-221(2009)
PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=20454443; DOI=10.1155/2010/904767
Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010)
PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)
PubMed=22885699; DOI=10.1038/nature11378
Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W.-M., Zhang M.-L., Wright G., Shaffer A.L. III, Hodson D.J., Buras E., Liu X.-L., Powell J.I., Yang Y.-D., Xu W.-H., Zhao H., Kohlhammer H., Rosenwald A., Kluin P.M., Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.C., Pittaluga S., Wilson W., Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Nature 490:116-120(2012)
具有增殖能力,因此这是巨核细胞系增加细胞数量的阶段。当巨核系祖细胞进一步分化为8-32倍体的巨核细胞时,胞质开始分化,内膜系统逐渐完备。最后有一种膜性物质把巨核细胞的胞质分隔成许多小区。当每个小区被完全隔开时即成为血小板,一个个血小板通过静脉窦窦壁内皮间的空隙从巨核细胞脱落,进入血流。 巨核细胞增殖、分化的调节机制类似于红细胞系生成的调节,至少受两种调节因子分别对两个分化阶段进行调节。这两种调节因子是:巨核系集落刺激因子(Meg-CSF)和促血小板生成素(thrombopoietin,TPO
淋巴瘤 HCT-8 回盲肠腺癌 Namalwa Burkitt`s淋巴瘤 HCe-8693 盲肠未分化腺癌 J urknt.Clone E6-1 白血病细胞 HR-8348 直肠腺癌 THP-1 单核细胞 BEL-7402 肝癌 U937 组织细胞淋巴瘤 BEL- 7404 肝癌 Raji Burkitt's淋巴瘤 BEL-7405 肝癌 MEG-01 成巨核细胞白血病 HepG2 肝细胞癌
谱 - + - - 用药史 - - - 停药后好转 巨核细胞数目 增多或正常 增多 减少 增多或正常 CFU-Meg 正常 正常
技术资料暂无技术资料 索取技术资料











